Cargando…

Prevalence and risk factors for unrecognized obstructive lung disease among urban drug users

BACKGROUND: Obstructive lung disease (OLD) is frequently unrecognized and undertreated. Urban drug users are at higher risk for OLD due to race, behavioral, and socioeconomic characteristics, yet little data exist on prevalence and risk factors associated with unrecognized OLD in this population. OB...

Descripción completa

Detalles Bibliográficos
Autores principales: Drummond, M Bradley, Kirk, Gregory D, Astemborski, Jacquie, McCormack, Meredith C, Marshall, Mariah M, Mehta, Shruti H, Wise, Robert A, Merlo, Christian A
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3048084/
https://www.ncbi.nlm.nih.gov/pubmed/21407821
http://dx.doi.org/10.2147/COPD.S15968
_version_ 1782199124477607936
author Drummond, M Bradley
Kirk, Gregory D
Astemborski, Jacquie
McCormack, Meredith C
Marshall, Mariah M
Mehta, Shruti H
Wise, Robert A
Merlo, Christian A
author_facet Drummond, M Bradley
Kirk, Gregory D
Astemborski, Jacquie
McCormack, Meredith C
Marshall, Mariah M
Mehta, Shruti H
Wise, Robert A
Merlo, Christian A
author_sort Drummond, M Bradley
collection PubMed
description BACKGROUND: Obstructive lung disease (OLD) is frequently unrecognized and undertreated. Urban drug users are at higher risk for OLD due to race, behavioral, and socioeconomic characteristics, yet little data exist on prevalence and risk factors associated with unrecognized OLD in this population. OBJECTIVE: The objective of this study is to determine the prevalence of unrecognized OLD in an urban population and identify the characteristics associated with lack of physician-diagnosed OLD. DESIGN: Cross-sectional analysis from the Acquired Immunodeficiency Syndrome Linked to the Intravenous Experience (ALIVE) study, an observational study of current and former injection drug users in Baltimore, Maryland, USA. PARTICIPANTS: All participants with spirometry-defined airflow obstruction were stratified by the presence or absence of physician diagnosis of OLD. MAIN MEASURES: Using cross-sectional demographic, clinical, and spirometric measurements, multivariable regression models were generated to identify factors independently associated with unrecognized OLD. KEY RESULTS: Of the 1083 participants evaluated in the ALIVE lung substudy, 176 (16.3%) met spirometric criteria for OLD. Of those, only 88 (50%) had a physician diagnosis of OLD. The prevalence of unrecognized OLD decreased as severity of airflow obstruction increased. Factors independently associated with unrecognized OLD were absence of respiratory symptoms (prevalence ratio [PR], 1.70; 95% confidence interval [CI]: 1.29–2.23; P < 0.01) and less severe dyspnea (PR, 0.83; 95% CI: 0.72–0.96, per point increase in dyspnea scale; P = 0.01). In the subset of human immunodeficiency virus (HIV)–infected participants, the use of antiretroviral therapy (ART) was independently associated with an increased prevalence of unrecognized OLD (PR, 1.93; 95% CI: 1.05–3.56; P = 0.03). CONCLUSIONS: In a cohort of current and former urban drug users, OLD is substantially underrecognized and associated with lack of respiratory symptoms. Relying on the presence of respiratory symptoms as a trigger to perform spirometry may result in a substantial underdiagnosis of OLD in this population. HIV-infected individuals receiving ART are a population particularly vulnerable to unrecognized OLD.
format Text
id pubmed-3048084
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-30480842011-03-15 Prevalence and risk factors for unrecognized obstructive lung disease among urban drug users Drummond, M Bradley Kirk, Gregory D Astemborski, Jacquie McCormack, Meredith C Marshall, Mariah M Mehta, Shruti H Wise, Robert A Merlo, Christian A Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: Obstructive lung disease (OLD) is frequently unrecognized and undertreated. Urban drug users are at higher risk for OLD due to race, behavioral, and socioeconomic characteristics, yet little data exist on prevalence and risk factors associated with unrecognized OLD in this population. OBJECTIVE: The objective of this study is to determine the prevalence of unrecognized OLD in an urban population and identify the characteristics associated with lack of physician-diagnosed OLD. DESIGN: Cross-sectional analysis from the Acquired Immunodeficiency Syndrome Linked to the Intravenous Experience (ALIVE) study, an observational study of current and former injection drug users in Baltimore, Maryland, USA. PARTICIPANTS: All participants with spirometry-defined airflow obstruction were stratified by the presence or absence of physician diagnosis of OLD. MAIN MEASURES: Using cross-sectional demographic, clinical, and spirometric measurements, multivariable regression models were generated to identify factors independently associated with unrecognized OLD. KEY RESULTS: Of the 1083 participants evaluated in the ALIVE lung substudy, 176 (16.3%) met spirometric criteria for OLD. Of those, only 88 (50%) had a physician diagnosis of OLD. The prevalence of unrecognized OLD decreased as severity of airflow obstruction increased. Factors independently associated with unrecognized OLD were absence of respiratory symptoms (prevalence ratio [PR], 1.70; 95% confidence interval [CI]: 1.29–2.23; P < 0.01) and less severe dyspnea (PR, 0.83; 95% CI: 0.72–0.96, per point increase in dyspnea scale; P = 0.01). In the subset of human immunodeficiency virus (HIV)–infected participants, the use of antiretroviral therapy (ART) was independently associated with an increased prevalence of unrecognized OLD (PR, 1.93; 95% CI: 1.05–3.56; P = 0.03). CONCLUSIONS: In a cohort of current and former urban drug users, OLD is substantially underrecognized and associated with lack of respiratory symptoms. Relying on the presence of respiratory symptoms as a trigger to perform spirometry may result in a substantial underdiagnosis of OLD in this population. HIV-infected individuals receiving ART are a population particularly vulnerable to unrecognized OLD. Dove Medical Press 2011 2011-01-19 /pmc/articles/PMC3048084/ /pubmed/21407821 http://dx.doi.org/10.2147/COPD.S15968 Text en © 2011 Drummond et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Drummond, M Bradley
Kirk, Gregory D
Astemborski, Jacquie
McCormack, Meredith C
Marshall, Mariah M
Mehta, Shruti H
Wise, Robert A
Merlo, Christian A
Prevalence and risk factors for unrecognized obstructive lung disease among urban drug users
title Prevalence and risk factors for unrecognized obstructive lung disease among urban drug users
title_full Prevalence and risk factors for unrecognized obstructive lung disease among urban drug users
title_fullStr Prevalence and risk factors for unrecognized obstructive lung disease among urban drug users
title_full_unstemmed Prevalence and risk factors for unrecognized obstructive lung disease among urban drug users
title_short Prevalence and risk factors for unrecognized obstructive lung disease among urban drug users
title_sort prevalence and risk factors for unrecognized obstructive lung disease among urban drug users
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3048084/
https://www.ncbi.nlm.nih.gov/pubmed/21407821
http://dx.doi.org/10.2147/COPD.S15968
work_keys_str_mv AT drummondmbradley prevalenceandriskfactorsforunrecognizedobstructivelungdiseaseamongurbandrugusers
AT kirkgregoryd prevalenceandriskfactorsforunrecognizedobstructivelungdiseaseamongurbandrugusers
AT astemborskijacquie prevalenceandriskfactorsforunrecognizedobstructivelungdiseaseamongurbandrugusers
AT mccormackmeredithc prevalenceandriskfactorsforunrecognizedobstructivelungdiseaseamongurbandrugusers
AT marshallmariahm prevalenceandriskfactorsforunrecognizedobstructivelungdiseaseamongurbandrugusers
AT mehtashrutih prevalenceandriskfactorsforunrecognizedobstructivelungdiseaseamongurbandrugusers
AT wiseroberta prevalenceandriskfactorsforunrecognizedobstructivelungdiseaseamongurbandrugusers
AT merlochristiana prevalenceandriskfactorsforunrecognizedobstructivelungdiseaseamongurbandrugusers